Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gene Alteration Protects from Artery Disease

January 28, 2011 7:03 am | News | Comments

A team of scientists has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.


Antibiotic Could Aid Cancer Fight

January 28, 2011 7:01 am | News | Comments

An antibiotic known for immunosuppression could also point the way to the development of new anti-cancer agents, researchers have reported. Tautomycetin targets an enzyme which plays an important role in cell activities such as proliferation and differentiation.


Tibotec Licenses Rilpivirine to Mylan

January 28, 2011 6:57 am | News | Comments

Mylan Inc. said it acquired a license to make and sell a generic version of a potential HIV drug in sub-Saharan Africa, India, and some developing countries.


Lilly Income Up 28%

January 28, 2011 6:55 am | by Tom Murphy | News | Comments

Eli Lilly and Co.'s fourth-quarter net income jumped 28 percent on sales from established drugs, but it expects earnings to slide this year as it faces generic competition and health care overhaul costs.


FDA Approves Mylan Generics

January 28, 2011 6:54 am | News | Comments

Drugmaker Mylan Inc. said the Food and Drug Administration has approved four dose amounts of its generic version of Shionogi Pharma's Sular tablets for treating hypertension.


FDA Questions GSK on Avodart

January 28, 2011 6:52 am | News | Comments

GlaxoSmithKline Plc. said the Food and Drug Administration is asking the company for more information before approving the drug Avodart for men at risk of getting prostate cancer.


Down Economy Hits Drugmakers

January 28, 2011 6:51 am | by Linda A. Johnson | News | Comments

Major drugmakers are reporting fourth-quarter earnings ranging from modestly better to bleak, but they're all showing dents from the macroeconomic forces that constrain the industry, now and for the foreseeable future.


Iniparib Fails Breast Cancer Trial

January 28, 2011 6:49 am | News | Comments

French drugmaker Sanofi-Aventis SA said a clinical trial showed its drug candidate iniparib did not improve survival or slow disease progression in patients with breast cancer.


Polypropylene Storage Tube

January 27, 2011 7:52 am | Product Releases | Comments

Micronic Europe has announced a new 1.4ml amber polypropylene storage tube that, used in conjunction with a secure screw cap, ensures the integrity of light sensitive biological samples even over long-term storage periods.


Reagent Trough

January 27, 2011 7:50 am | Product Releases | Comments

Tecan has launched a new 25 ml trough designed to reduce waste of valuable reagents in automated liquid handling applications. These troughs have a conical base design to minimize the inaccessible liquid volume.


Nanoparticles Speed Wound Healing

January 27, 2011 7:45 am | News | Comments

Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers.


New Anti-HIV Gene Therapy Developed

January 27, 2011 7:37 am | News | Comments

An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a newly published paper.


BioFocus Working with Lundbeck

January 27, 2011 7:23 am | News | Comments

BioFocus announced that a subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck’s liquid chemical library collection.


Cetero Finishes 20,000th Study

January 27, 2011 7:17 am | News | Comments

Cetero Research has conducted its milestone 20,000th early-phase clinical study. This achievement highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology, and generic clients.


Provectus Completes Liver Cancer Trial

January 27, 2011 7:13 am | News | Comments

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.